Monofer Iron Isomaltoside Injection

1. Indications and Usage
Iron Deficiency Anemia: Treatment of anemia due to iron deficiency in patients who have failed oral iron therapy, cannot tolerate oral iron, or require rapid iron replenishment.
Chronic Kidney Disease: Management of iron deficiency in adult patients with chronic kidney disease on dialysis.
2. Dosage and Administration
Route of Administration: For Intravenous (IV) Use ONLY (IV bolus or IV infusion) or direct injection into the venous line of a dialyzer.
Recommended Dosage: The total iron deficit must be calculated. A single dose can be up to 20 mg/kg body weight (max 1000 mg).
Critical Administration Instructions:
IV Bolus: Maximum 500 mg per injection, at a rate not exceeding 250 mg iron/minute. Can be undiluted or diluted in max 20 mL 0.9% NaCl.
IV Infusion: Dilute in 0.9% NaCl (max 500 mL). Final concentration must not be lower than 1 mg iron/mL. Infusion time must be ≥15 min for ≤1000 mg, or ≥30 min for >1000 mg.
Observation: Patients must be observed for at least 30 minutes after administration for signs of hypersensitivity.
3. Mechanism of Action
Stable Complex: Iron is tightly bound in a carbohydrate-iron(III) complex (isomaltoside), resembling the ferritin structure.
Controlled Release: The complex is internalized by reticuloendothelial cells via receptor-mediated endocytosis, where iron is slowly and controllably released for erythropoiesis without flooding the plasma iron-binding capacity.
4. Safety and Warnings
Hypersensitivity: Severe and potentially life-threatening anaphylactic/anaphylactoid reactions may occur. Resuscitation equipment and trained personnel must be present during administration.
Iron Overload: Avoid use in patients with iron overload (e.g., hemochromatosis) or decompensated liver disease.
Infection: Use with caution in acute or chronic infections; patients with bacteremia should not receive this drug.
Extravasation: Avoid extravasation to prevent skin irritation and long-term brown discoloration.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Injection site reactions, nausea, headache, dizziness, and rash.
Delayed Reactions: Severe joint pain and myalgia may occur within hours to days post-administration.
Clinical Research Highlights: Clinical trials demonstrate that Iron Isomaltoside allows for high-dose single-bolus administration with a significantly lower risk of hypersensitivity compared to older iron dextran formulations.
6. Drug Interactions
Oral Iron Preparations: Concomitant use may decrease the absorption of oral iron; oral iron should be discontinued prior to IV administration.
CYP3A4 Substrates: Theoretical potential for interaction, though clinical significance is currently unknown.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Iron(III) hydroxide isomaltoside complex.
Appearance: Dark brown, opaque solution.
Packaging: Single-dose vial (1 mL containing 100 mg iron, 5 mL containing 500 mg iron, etc.).
Storage: Store at 2°C to 8°C. Do not freeze. Protect from light.